Paul Tudor Jones Sarepta Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $4.23 Million - $7.83 Million	62,800 New	62,800 $6.06 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $1.86 Million - $2.47 Million	-15,851 Reduced 52.12%	14,561 $2.01 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $487,758 - $638,980	-4,836 Reduced 13.72%	30,412 $3.94 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $2.67 Million - $4.2 Million	35,248 New	35,248 $3.9 Million
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $274,770 - $387,632	-4,383 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $106,218 - $152,086	1,682 Added 62.27%	4,383 $342,000
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $208,733 - $268,533	2,701 New	2,701 $243,000
Q3 2021 Nov 15, 2021	SELL	$65.97 - $92.48 $3.74 Million - $5.24 Million	-56,657 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $3.48 Million - $4.35 Million	50,173 Added 773.8%	56,657 $4.41 Million
Q1 2021 May 17, 2021	BUY	$72.25 - $168.95 $265,302 - $620,384	3,672 Added 130.58%	6,484 $483,000
Q4 2020 Feb 16, 2021	BUY	$125.56 - $178.74 $353,074 - $502,616	2,812 New	2,812 $479,000
Q3 2020 Nov 16, 2020	SELL	$127.12 - $172.34 $1.78 Million - $2.42 Million	-14,034 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$93.0 - $171.7 $1.31 Million - $2.41 Million	14,034 New	14,034 $2.25 Million
Q3 2018 Nov 14, 2018	SELL	$115.31 - $161.51 $4.7 Million - $6.58 Million	-40,761 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$71.74 - $153.69 $2.92 Million - $6.26 Million	40,761 New	40,761 $5.39 Million

526

84.4M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.97B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.